| Rankin, Bruce |
| Completed | 4 | 580 | US | Galcanezumab, LY2951742, Rimegepant, Placebo | Eli Lilly and Company | Migraine, Episodic Migraine | 05/23 | 05/23 | | |
|
| Active, not recruiting | 3 | 409 | Europe, US | Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system | Averitas Pharma, Inc., Averitas Pharma, Inc. | Post Surgical Neuropathic Pain | 01/25 | 08/25 | | |
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
|
|
| Completed | 3 | 523 | Europe, US | buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo | Annovis Bio Inc., TFS Trial Form Support | Parkinson's Disease, Idiopathic | 12/23 | 12/23 | | |
NCT05171673: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants with Minor Soft Tissue Injury |
|
|
| Completed | 3 | 151 | US | Licart™ (diclofenac epolamine) topical system, diclofenac epolamine | IBSA Institut Biochimique SA | Soft Tissue Injuries | 06/24 | 07/24 | | |
| Active, not recruiting | 3 | 650 | US | Cytisinicline, Cytisine | Achieve Life Sciences | Smoking Cessation, Vaping Cessation | 12/25 | 12/25 | | |
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD |
|
|
| Completed | 2/3 | 320 | US | Buntanetap/Posiphen, Posiphen Tartrate, Placebo | Annovis Bio Inc. | Alzheimer Disease | 02/24 | 02/24 | | |
NCT05925127: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines |
|
|
| Completed | 2/3 | 994 | US | NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), Omicron XBB.1.5, NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5, Omicron Subvariant/Prototype Licensed mRNA Vaccine | Novavax | COVID-19 | 05/24 | 05/24 | | |
| Completed | 2/3 | 554 | US | ATH-1017, Placebo | Athira Pharma | Alzheimer Disease, Dementia of Alzheimer Type | 07/24 | 07/24 | | |
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain |
|
|
| Active, not recruiting | 2/3 | 602 | US, RoW | Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly | Paradigm Biopharmaceuticals USA (INC) | Osteoarthritis, Knee | 10/24 | 01/25 | | |
OA05, NCT05620563: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain |
|
|
| Completed | 2 | 147 | US | LY3857210, Placebo | Eli Lilly and Company | Osteoarthritis | 06/23 | 06/23 | | |
NCT05630196: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain |
|
|
| Completed | 2 | 138 | US | LY3857210, Placebo | Eli Lilly and Company | Chronic Low-back Pain | 06/23 | 06/23 | | |
NCT05620576: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05). |
|
|
| Completed | 2 | 131 | US | LY3857210, Placebo | Eli Lilly and Company | Diabetic Peripheral Neuropathic Pain | 07/23 | 08/23 | | |
NCT05837338: Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154 |
|
|
| Completed | 2 | 24 | US | BXP154, Placebo | Bio 54, LLC | Wound Bleeding | 07/23 | 07/23 | | |
NCT06205615: Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B |
|
|
| Completed | 2 | 24 | US | BXP154B, Placebo | Bio 54, LLC | Wound Bleeding | 03/24 | 03/24 | | |
BMT-801, NCT06565611: A Phase 2 Study Evaluating the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity |
|
|
| Active, not recruiting | 2 | 108 | US | bremelanotide, tirzepatide | Palatin Technologies, Inc | Obesity | 01/25 | 03/25 | | |
| Recruiting | 2 | 282 | Europe, Canada, US, RoW | GSK4527226, Placebo | GlaxoSmithKline, Alector Inc. | Alzheimer's Disease | 12/26 | 02/29 | | |
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain |
|
|
| Recruiting | 2 | 10000 | US | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo | Eli Lilly and Company | Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain | 04/27 | 04/27 | | |
DISC-0974-103, NCT05745883: Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants with CKD and Anemia |
|
|
| Recruiting | 1 | 50 | US | DISC-0974, Placebo | Disc Medicine, Inc | Chronic Kidney Diseases, Anemia of Chronic Kidney Disease | 09/25 | 05/26 | | |
NCT05916560: A Study of LY3437943 in Participants With Impaired and Normal Liver Function |
|
|
| Recruiting | 1 | 37 | US | LY3437943 | Eli Lilly and Company | Healthy, Hepatic Insufficiency | 03/25 | 03/25 | | |
NCT04451408: A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants |
|
|
| Active, not recruiting | 1 | 224 | Japan, US | LY3372993, Placebo | Eli Lilly and Company | Alzheimer Disease, Healthy | 11/24 | 11/24 | | |
| Recruiting | N/A | 70 | US | | Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals | Parkinson Disease | 08/25 | 09/25 | | |
| Vayser, Dean |
| Active, not recruiting | 3 | 409 | Europe, US | Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system | Averitas Pharma, Inc., Averitas Pharma, Inc. | Post Surgical Neuropathic Pain | 01/25 | 08/25 | | |
| Recruiting | 2 | 80 | US, RoW | TP-102, Placebo | Technophage, SA, VectorB2B | Diabetic Foot Infection | 12/24 | 12/24 | | |
PL-5, NCT06189638: Phase II Study to Evaluate Efficacy and Safety of AMP Peptide in Mild Infections of Diabetic Foot Ulcers |
|
|
| Active, not recruiting | 2 | 90 | US | Antimicrobial Peptide PL-5 Topical Spray and Placebo, AMP PL-5 and Placebo | Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., Parexel | Diabetic Foot Ulcers | 12/26 | 12/27 | | |
NCT03855514: Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 200 | US | NuShield | Organogenesis | Diabetic Foot Ulcer | 11/21 | 12/21 | | |
NCT04901013: Clinical Study Of Affinity Versus SOC In The Management Of VLUs |
|
|
| Recruiting | N/A | 200 | US | Affinity | Organogenesis | Venous Leg Ulcer | 03/23 | 06/23 | | |
NCT05087758: Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 120 | US | Matrion, Conventional Care Wound Management | LifeNet Health | Diabetic Foot, Lower Extremity Wound | 12/23 | 03/24 | | |
NCT04927702: Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU) |
|
|
| Terminated | N/A | 47 | US | Synthetic Hybrid-Scale Fiber Matrix, Restrata, Standard of Care, Living Cellular Skin Substitute, Apligraf | Acera Surgical, Inc. | Diabetic Foot Ulcer, Venous Leg Ulcer | 07/24 | 08/24 | | |
NCT06515093: Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC |
|
|
| Recruiting | N/A | 180 | US | SanoGraft, PelloGraft | Surgenex | Diabetic Foot Ulcer, Venous Leg Ulcer | 06/25 | 08/25 | | |
